Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Eleonora Mozzillo"'
Autor:
Francesca Foschini, Fabiana Napolitano, Alberto Servetto, Roberta Marciano, Eleonora Mozzillo, Anna Chiara Carratù, Antonio Santaniello, Pietro De Placido, Priscilla Cascetta, Giovanni Butturini, Isabella Frigerio, Paolo Regi, Nicola Silvestris, Sabina Delcuratolo, Enrico Vasile, Caterina Vivaldi, Cataldo Bianco, Sabino De Placido, Luigi Formisano, Roberto Bianco
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Pancreatic adenocarcinoma is the fourth leading cause of cancer-related death. In cases with metastasis, the combination of 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) or gemcitabine-based chemotherapy regimens are considered
Externí odkaz:
https://doaj.org/article/32bd07d5963c4313b2b9edfae2483916
Autor:
Alberto Servetto, Antonio Santaniello, Fabiana Napolitano, Francesca Foschini, Roberta Marciano, Eleonora Mozzillo, Priscilla Cascetta, Anna Rita Amato, Maria Rosaria Augurio, Lucia Maresca, Pietro De Placido, Sabino De Placido, Luigi Formisano, Roberto Bianco
Publikováno v:
Cancers, Vol 13, Iss 19, p 4939 (2021)
Patients with locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC) do not present distant metastases but are not eligible for surgery upfront. Chemotherapy regimens, such as FOLFIRINOX (FFN) or nab-paclitaxel plus gemcitabine (GemNab) in com
Externí odkaz:
https://doaj.org/article/a4a843550ee74094af2f98294750493f
Autor:
Fabiana Napolitano, Luigi Formisano, Alessandro Giardino, Roberto Girelli, Alberto Servetto, Antonio Santaniello, Francesca Foschini, Roberta Marciano, Eleonora Mozzillo, Anna Chiara Carratù, Priscilla Cascetta, Pietro De Placido, Sabino De Placido, Roberto Bianco
Publikováno v:
Cancers, Vol 11, Iss 7, p 981 (2019)
The optimal therapeutic strategy for locally advanced pancreatic cancer patients (LAPC) has not yet been established. Our aim is to evaluate how surgery after neoadjuvant treatment with either FOLFIRINOX (FFN) or Gemcitabine-NabPaclitaxel (GemNab) af
Externí odkaz:
https://doaj.org/article/9a3c6a86afdc413d85baaecfa9a4cd77
Autor:
Roberta Marciano, Alberto Servetto, Concetta Di Mauro, Roberto Bianco, Luigi Formisano, Priscilla Cascetta, Pietro De Placido, Fabiana Napolitano, Ada Pesapane, Annachiara Carratù, Stefania Belli, Eleonora Mozzillo, Antonio Santaniello, Daniela Esposito
Publikováno v:
Cancer Research. 80:P3-06
Background: CDK4/6 inhibitors have been approved in combination with endocrine therapy for the treatment of estrogen receptor positive (ER+) metastatic breast cancer. The goal of this study was to discover mechanisms of resistance to ER antagonists a
Autor:
Fabiana Napolitano, Sabino De Placido, Lucia Maresca, Antonio Santaniello, R. Marciano, Roberto Bianco, Eleonora Mozzillo, Alberto Servetto, Francesca Foschini, Luigi Formisano, Priscilla Cascetta, Pietro De Placido, Anna Rita Amato, Maria Rosaria Augurio
Publikováno v:
Cancers, Vol 13, Iss 4939, p 4939 (2021)
Cancers
Volume 13
Issue 19
Cancers
Volume 13
Issue 19
Patients with locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC) do not present distant metastases but are not eligible for surgery upfront. Chemotherapy regimens, such as FOLFIRINOX (FFN) or nab-paclitaxel plus gemcitabine (GemNab) in com
Autor:
Giovanni Butturini, Roberta Marciano, Luigi Formisano, Cataldo Bianco, Eleonora Mozzillo, Anna Chiara Carratù, Sabino De Placido, Isabella Frigerio, Francesca Foschini, Priscilla Cascetta, Pietro De Placido, Roberto Bianco, Fabiana Napolitano, Antonio Santaniello, Sabina Delcuratolo, Nicola Silvestris, P. Regi, Enrico Vasile, Alberto Servetto, Caterina Vivaldi
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Pancreatic adenocarcinoma is the fourth leading cause of cancer-related death. In cases with metastasis, the combination of 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) or gemcitabine-based chemotherapy regimens are considered
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e9004761b6144ee877e2bf946e619b3
http://hdl.handle.net/11568/1114474
http://hdl.handle.net/11568/1114474
Autor:
Luisa Piccin, Silvana Del Vecchio, Eleonora Mozzillo, Sara Pellegrino, Sabino De Placido, Rosa Fonti, Vincenzo Damiano, Elide Matano, Emanuela Mazziotti
Publikováno v:
Annals of nuclear medicine 33 (2019): 937–944. doi:10.1007/s12149-019-01407-z
info:cnr-pdr/source/autori:Pellegrino, Sara; Fonti, Rosa; Mazziotti, Emanuela; Piccin, Luisa; Mozzillo, Eleonora; Iano, Vincenzo Dam; Matano, Elide; De Placido, Sabino; Del Vecchi, Silvana/titolo:Total metabolic tumor volume by 18F-FDG PET%2FCT for the prediction of outcome in patients with non-small cell lung cancer/doi:10.1007%2Fs12149-019-01407-z/rivista:Annals of nuclear medicine/anno:2019/pagina_da:937/pagina_a:944/intervallo_pagine:937–944/volume:33
info:cnr-pdr/source/autori:Pellegrino, Sara; Fonti, Rosa; Mazziotti, Emanuela; Piccin, Luisa; Mozzillo, Eleonora; Iano, Vincenzo Dam; Matano, Elide; De Placido, Sabino; Del Vecchi, Silvana/titolo:Total metabolic tumor volume by 18F-FDG PET%2FCT for the prediction of outcome in patients with non-small cell lung cancer/doi:10.1007%2Fs12149-019-01407-z/rivista:Annals of nuclear medicine/anno:2019/pagina_da:937/pagina_a:944/intervallo_pagine:937–944/volume:33
Objective Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) are imaging parameters derived from 18F-FDG PET/CT that have been proposed for risk stratification of cancer patients. The aim of our study was to test whether these whole-body
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b7c27391330e61137a734b46af47d13
http://hdl.handle.net/11588/765016
http://hdl.handle.net/11588/765016
Autor:
Francesca Foschini, Roberta Marciano, Luigi Formisano, Roberto Bianco, Alberto Servetto, Roberto Girelli, Alessandro Giardino, Anna Chiara Carratù, Fabiana Napolitano, Priscilla Cascetta, Antonio Santaniello, Pietro De Placido, Eleonora Mozzillo, Sabino De Placido
Publikováno v:
Cancers, Vol 11, Iss 7, p 981 (2019)
Cancers
Volume 11
Issue 7
Cancers
Volume 11
Issue 7
The optimal therapeutic strategy for locally advanced pancreatic cancer patients (LAPC) has not yet been established. Our aim is to evaluate how surgery after neoadjuvant treatment with either FOLFIRINOX (FFN) or Gemcitabine-NabPaclitaxel (GemNab) af
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca16a3cc1f13d61caa0d751cf5b33871
http://hdl.handle.net/11588/765610
http://hdl.handle.net/11588/765610
Autor:
Stefania Belli, Annachiara Carratù, Fabiana Napolitano, Roberto Bianco, Ada Pesapane, Luigi Formisano, Priscilla Cascetta, Concetta Di Mauro, Antonio Santaniello, Eleonora Mozzillo, Alberto Servetto, Pietro De Placido, Roberta Marciano, Daniela Esposito
Publikováno v:
Cancer Research. 80:P5-04
Background: Recently, immune check-point inhibitors have shown efficacy in triple-negative breast cancer (TNBC). Since Hedgehog (Hh) signalling mediates crosstalk between breast cancer cells and tumor-infiltrating immune cells, we investigated the me
Autor:
P. De Placido, Alberto Servetto, Luigi Formisano, Francesca Foschini, R. Marciano, Roberto Bianco, Filomena Napolitano, Annachiara Carratù, Eleonora Mozzillo, Priscilla Cascetta, Antonio Santaniello
Publikováno v:
Annals of Oncology. 30:iv52-iv53